Hytest
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|---|---|
Revenues | 15.7m | 21.6m | 21.3m | 22.3m | 24.7m | 26.6m | 32.5m |
% growth | - | 38 % | (1 %) | 5 % | 11 % | 8 % | 22 % |
EBITDA | 6.2m | 9.8m | 9.3m | 6.5m | 11.1m | 10.8m | 17.0m |
% EBITDA margin | 39 % | 45 % | 44 % | 29 % | 45 % | 41 % | 52 % |
Profit | 5.0m | 7.9m | 7.4m | 5.2m | (<1m) | 3.4m | 2.1m |
% profit margin | 32 % | 37 % | 35 % | 23 % | - | 13 % | 6 % |
R&D budget | - | 20.0m | 20.0m | 20.0m | 20.0m | 30.0m | - |
R&D % of revenue | - | 93 % | 94 % | 90 % | 81 % | 113 % | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | N/A | Debt | |
€545m Valuation: €545m 20.5x EV/LTM Revenues 50.3x EV/LTM EBITDA | Acquisition | ||
Total Funding | - |
Related Content
Recent News about Hytest
EditHyTest is a leading provider of innovative solutions for assay development and research applications, specializing in high-quality immunological reagents. The company serves a diverse range of clients, including diagnostic companies, research institutions, and healthcare providers. Operating in the global healthcare and diagnostics market, HyTest focuses on key areas such as cardiac markers, infectious disease antibodies, and autoimmune disease reagents. The business model revolves around the production and sale of monoclonal and polyclonal antibodies, antigens, and other immunological reagents. Revenue is generated through direct sales to clients and partnerships with diagnostic companies. HyTest also offers specialized products for COVID-19 diagnostics, including monoclonal antibodies and biomarkers to distinguish severity and prognosis. The company is committed to advancing scientific research and improving diagnostic accuracy through its high-quality products and services.
Keywords: immunological reagents, cardiac markers, infectious disease, autoimmune disease, monoclonal antibodies, polyclonal antibodies, antigens, diagnostics, assay development, healthcare.